, , , ,

TechInnovation returns in 2024 to explore Sustainable Urban Living

27 August 2024 – Singapore – TechInnovation 2024, IPI Singapore’s flagship event, is set to return this year from 28 – 30 October at Marina Bay Sands, Level 4, Roselle-Simpor Ballroom, as a premier event dedicated to exploring Sustainable Urban Living. 

Organised by IPI, the event will bring together innovators, industry leaders, and key collaborators to address sustainability, innovation, and digital challenges. Over three days, the event will focus on key themes:

Featured Speakers

TechInnovation 2024 will feature prominent speakers, panellists and moderators, who are leaders in their fields, sharing their insights and experiences:

Media Accreditation

To apply for media accreditation to attend TechInnovation 2024, please visit our press centre here.

For more information about TechInnovation 2024, please visit the TechInnovation website.

About IPI & TechInnovation 2024: 

IPI is an innovation leader helping businesses thrive through sustainability, innovation, and digital adoption. Its flagship event, TechInnovation 2024, empowers businesses with comprehensive solutions, collaboration, and insights. The event features a robust conference program, a cutting-edge technology showcase, and strategic B2B matchmaking services. This year’s focus on Sustainable Urban Living includes themes such as Future Forward Cities, a Future-Ready Food Industry, and Healthcare Horizons. TechInnovation gathers industry leaders, professionals, and entrepreneurs, showcasing over 150+ innovations for urban living, food, health and wellness.

Visit the IPI Singapore website for more information.

More Articles from the Medical Industry

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies …

Qiagen N.V. – QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships

Two new partnerships enhance QIAGEN’s capabilities to support pharma partner clinical trials with significant expansion of MRD capabilities – especially …

Pre-Event Coverage for Pharmtech & Ingredients 2025

Pharmtech & Ingredients, Eurasia’s leading exhibition for pharmaceutical manufacturing, returns for its 27th edition from 25–28 November 2025 at Crocus …

Korea Innovation QuickFire Challenge: Targeting Neuroscience

Overview Despite significant advances in understanding and treating nervous system disorders, millions of people worldwide continue to live with neurodegenerative …
Share via
Copy link